TRDA
Entrada Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$6.75
−2.17%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.98
- Revenue estimate
- $2.1M
Latest reported
- Last report date
- Aug 5, 2026
- EPS actual
- -$1.01
- EPS estimate
- -$0.97
- Revenue actual
- $898.0K
- Revenue estimate
- $2.3M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 7
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -4.0%
- Revenue beats (12Q)
- 3
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 5, 2026 | -$0.97 | -$1.01 | Miss -3.72% | $898.0K |
| May 7, 2026 | -$1.06 | -$0.95 | Beat 10.38% | $875.0K |
| Nov 6, 2025 | -$1.04 | -$1.06 | Miss -1.92% | $1.6M |
| Aug 6, 2025 | -$0.86 | -$1.04 | Miss -20.93% | $1.9M |
| May 8, 2025 | -$0.78 | -$0.42 | Beat 46.15% | $20.6M |
| Feb 27, 2025 | -$0.66 | $0.03 | Beat 104.55% | $37.4M |
| Mar 13, 2024 | -$0.07 | -$0.29 | Miss -314.29% | $41.8M |
| Mar 6, 2023 | -$0.84 | -$0.79 | Beat 5.95% | — |
| Aug 11, 2022 | -$0.72 | -$0.74 | Miss -2.78% | — |
| May 12, 2022 | -$0.65 | -$0.69 | Miss -6.15% | — |
| Mar 15, 2022 | -$1.28 | -$0.89 | Beat 30.47% | — |
| Dec 9, 2021 | -$0.87 | -$9.78 | Miss -1024.14% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026